UMSCs Attenuate LPS/D-GalN-induced Acute Liver Failure in Mice by Down-regulating the MyD88/NF-κB Pathway

Hailing Liao, Siying Du, Ting Jiang, Mengyao Zheng, Zhao Xiang and Jinhui Yang*

Department of Digestive Medicine, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

Received: 9 December 2020 | Revised: 13 January 2021 | Accepted: 23 March 2021 | Published: 22 April 2021

Abstract

Background and Aims: Acute liver failure (ALF) is an inflammatory process of acute liver cell injury. Mesenchymal stem cells (MSCs) are undifferentiated, primitive cells with anti-inflammatory, anti-apoptotic, and multi-directional differentiation abilities. This study aimed to explore the therapeutic mechanism of umbilical cord (U)MSCs in ALF. Methods: D-galactosamine (D-GalN) combined with lipopolysaccharide (LPS) was used to establish an ALF model. After model establishment, UMSCs were injected via the tail vein. After UMSC transplantation, the number of mouse deaths was monitored every 12 h. A fully automatic biochemical analyzer was used to detect changes in biochemical analysis. Pathological changes were observed by staining with hematoxylin and eosin. The expression of MyD88 was detected by immunohistochemical analysis, quantitative reverse transcription, and western blotting. The expression of NF-κB was detected by quantitative reverse transcription, western blotting, and immunohistochemical analysis. The expression of Bcl-2, Bax were detected by quantitative reverse transcription, western blotting. The expression of TNF-α, IL-1β, IL-6, and tumor necrosis factor (NF)-κB p65 underwent nuclear translocation, inhibiting the production of the inflammatory factors (IκB). Additionally, NF-κB p65 underwent nuclear translocation, inhibiting the production of the inflammatory factors (IκB). Furthermore, the expression of MyD88, NF-κB p65 underwent nuclear translocation, inhibiting the production of the inflammatory factors (IκB). Finally, the expression of MyD88, NF-κB p65 underwent nuclear translocation, inhibiting the production of the inflammatory factors (IκB).

Results: The 48-h survival rate of the UMSC-treated group was significantly higher than that of the LPS/D-GalN-exposed group. After 24 h of LPS/D-GalN exposure, UMSCs reduced serum alanine aminotransferase and aspartate aminotransferase levels and improved the liver structure. Western blot and real-time fluorescence quantitative nucleic acid amplification analyses showed that UMSCs decreased MyD88 expression, thereby inhibiting LPS/D-GalN-induced phosphorylation and degradation of inhibitor of nuclear factor (NF)-κB (IκB). Additionally, NF-κB p65 underwent nuclear translocation, inhibiting the production of the inflammatory factors interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α, and played a protective role in ALF by down-regulating the pro-apoptotic gene Bax and up-regulating the anti-apoptotic gene Bcl-2. In summary, these findings indicate that UMSCs play a protective role in LPS/D-GalN-induced acute liver injury via inhibition of the MyD88 pathway and subsequent inhibition of NF-κB-mediated cytokine production. Conclusions: Through the above mechanisms, UMSCs can effectively reduce LPS/D-GalN-induced ALF, reduce mouse mortality, and restore damaged liver function and damaged liver tissue.

Citation of this article: Liao H, Du S, Jiang T, Zheng M, Xiang Z, Yang J. UMSCs attenuate LPS/D-GalN-induced acute liver failure in mice by down-regulating the MyD88/NF-κB pathway. J Clin Transl Hepatol 2021;9(5):690–701. doi: 10.14218/JCTH.2020.00157.

Introduction

Acute liver failure (ALF) refers mainly to interactions among multiple factors that lead to the acute necrosis of liver cells and rapid loss of liver function; in such, liver function is decimated, and severe liver disease may eventually lead to functional failure. This syndrome1-2 is clinically characterized by acute onset, rapid progression, and high mortality. Since 1983, liver transplantation has been recognized as the most effective treatment for ALF.3 However, as living standards have continuously improved, the incidence of ALF has also increased annually. Thus, the gap between the number of patients awaiting transplant and the supply of organs is widening, and the development of a treatment to replace liver transplantation is urgently needed. As early as the 1980s, Arnold Caplan proposed mesenchymal stem cells (MSCs) and MSC-based treatments.4 Studies have reported that transplanted MSCs can secrete many cytokines, promote liver tissue repair, inhibit immune cell proliferation and migration to the liver, and regulate liver function and the systemic immune inflammatory response.3 Knowledge on stem cell (SC) biology has increased rapidly, opening new avenues for SC-based therapies and the use of SCs as a cell therapy platform for ALF.5

SC transplantation therapy has become another important option to improve ALF treatment. SCs are undifferentiated, primitive progenitor cells with the characteristics of self-renewal, proliferation potential, and differentiation potential,6 and they can differentiate into multiple functional cells under certain conditions. In addition, studies have shown that SCs have other characteristics, including anti-inflammatory activity, apoptosis resistance, antioxidant activity, immunosuppressive activity, tissue repair capability, and growth factor expression.7 In humans, umbilical cord (U)MSCs can be derived from different compartments of the organ, including the amniotic membrane region, Wharton’s jelly, perivascular zone8

Keywords: Acute liver failure; Stem cells; Inflammation; Signaling pathway. Abbreviations: ALF, acute liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; D-GalN, D-galactosamine; IL-1β, interleukin-1β; IL-6, interleukin-6; IκB, inhibitor of nuclear factor-κB; LPS, lipopolysaccharide; MSCs, mesenchymal stem cells; My D88, Myeloid differentiation factor 88; NF-κB, nuclear factor-κB; P-IkB, phosphorylated-IκB; TBil, total bilirubin; TNF-α, tumor necrosis factor-α; UMSCs, umbilical cord mesenchymal stem cells.

Correspondence to: Jinhui Yang, Department of Digestive Medicine, The Second Affiliated Hospital of Kunming Medical University, No. 374 Yunnan Burma Road, West District, Kunming, Yunnan 650031, China. ORCID: https://orcid.org/0000-0002-5733-0647. Tel: +86-13608712810, E-mail: yangjinhui111@163.com

Copyright: © 2021 The Author(s). This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided.

*This article has been published in Journal of Clinical and Translational Hepatology at https://doi.org/10.14218/JCTH.2020.00157 and can also be viewed on the Journal’s website at http://www.jcthnet.com*. 

Journal of Clinical and Translational Hepatology 2021 vol. 9(5) | 690–701
DOI: 10.14218/JCTH.2020.00157
of the vascular wall, and endothelial region in the middle and outer membrane region. Among all MSC groups, UMSCs have a strong proliferative ability. Research shows that UMSCs can maintain a stable doubling time in multiple passages, as the doubling time of the bone mesenchymal stem cells increased significantly after only six passages. Compared to other MSCs, UMSCs are more primitive, and because of their unique gene expression profile, UMSCs produce few teratomas. In addition, because the placenta has a barrier, there is a low risk of infection from UMSC transplants, and hence, UMSCs are more suitable for clinical research.

Lipopolysaccharide (LPS) combined with D-galactosamine (D-GalN) is often used to establish animal models of liver failure, which is characterized by the activation of nuclear factor (NF)-κB and the excessive secretion of inflammatory cytokines/mediating factors, leading to a systemic inflammatory response. Accumulating evidence indicates that various proinflammatory cytokines/mediators, such as tumor necrosis factor (TNF)-α, leukocyte-derived interleukin (IL)-1β, IL-6, inducible nitric oxide synthase and cyclooxygenase-2, are involved in LPS/GaIN-induced liver toxicity. Therefore, inhibiting the inflammatory response may be an approach for treating liver failure.

Myeloid differentiation factor (MyD88) is an important Toll-like receptor (TLR)/IL-1 receptor superfamily member, and transduction of all TLRs into the cytoplasm by MyD88, in whole or in part, makes it a necessary adaptor protein to activate NF-κB and the mitogen-activated protein kinase signaling pathway. LPS is recognized by TLR4 expressed by the cell and activates innate immunity through a MyD88-dependent pathway. Studies have shown that after genetic knockout of MyD88 in mice, LPS-induced activity almost completely disappeared. After intraperitoneal injection of high concentrations of LPS, mice can survive for more than 96 h, but all mice without MyD88 gene knockout die within 96 h, indicating that MyD88 plays an important role in LPS activation. NF-κB is comprised of the p50 and p65 subunits; in addition, the inhibitor of NF-κB (IκB) is essential for host defense and mediates expression of the above-mentioned pro-inflammatory mediators and cytokines. In addition, NF-κB controls apoptosis. Therefore, the inhibition of pro-inflammatory mediators and apoptosis is considered a potential strategy for ALF prevention and treatment. Studies have shown that overactivated MyD88 signaling is a key factor in the development of many immune-mediated diseases, which provides us with new therapeutic areas targeting MyD88 signaling pathways to treat these diseases.

On the basis of the characteristics of the LPS/D-GalN model, we suspect that UMSCs may protect liver injury by inhibiting the inflammatory pathway and apoptosis pathway. Therefore, in this study, a mouse model of ALF was established via the administration of D-GalN combined with LPS. The therapeutic effect of UMSCs on ALF was evaluated, and the potential mechanism was revealed.

Methods

Mouse model establishment and cell transplantation

Healthy female BALB/c mice (weight, 20–22 g; age, 6–8 weeks; no specific pathogen grade) were purchased from the Animal Experiment Center of Kunming Medical University (China). Mice were housed in an environmentally controlled room (temperature, 24°C; humidity, 40–80%) under a 12-h dark/12-h light cycle and had free access to food and water. All experiments were approved by the Medical Ethics Committee of Kunming Medical University and were conducted in accordance with the experimental animal care principles of the University. Sixty-eight mice were randomly divided into three groups, namely, the control group (n=10), the LPS/D-GalN group (n=28), and the LPS/D-GalN+UMSCs group (n=28). D-GalN (900 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) was administered via intraperitoneal injection at 12-h intervals for a total of two times. After the second intraperitoneal injection of D-GalN, LPS (10 µg/kg; Sigma-Aldrich) was also administered to establish the ALF model. At 24 h after the LPS/D-GalN injection, mice in the LPS/D-GalN + UMSCs group were injected with UMSCs (5×10^6 cells/mouse; Beike Bio, Shenzhen, China) via the tail vein. Mice in the LPS/D-GalN group were not given any treatment. At 12 h, 1 day, 2 days, 5 days, 7 days, 14 days, 21 days, and 28 days after cell transplantation, mice were anaesthetized with 40 mg/kg pentobarbital sodium (Sigma-Aldrich) via intraperitoneal injection, and blood samples and liver tissue samples were collected for histopathological studies and protein detection.

Long-term survival analysis and biochemical analysis

After UMSC transplantation, the number of mouse deaths was monitored every 12 h. At 12 h, 24 h, and 48 h after UMSC transplantation, mice were anaesthetized by the intraperitoneal injection of pentobarbital sodium. Mouse eyeballs were then removed for blood collection. Each blood sample was incubated at room temperature for 30 min and was then centrifuged at 3,000 rpm for 15 min at 4°C. The upper layer of serum was stored at −20°C. A fully automatic biochemical analyzer (Beckman AU-5421; Beckman-Coulter, Brea, CA, USA) was used to detect changes in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBI) levels.

Pathological and immunological analyses

Mice were sacrificed at the designated time points (12 h, 1 day, 2 days, 5 days, 7 days, 14 days, 21 days, and 28 days) after cell transplantation. Liver lobes were excised from the same site and fixed with 4% paraformaldehyde (Solarbio, Beijing, China) for 24 h for histological and immunological analyses. Paraffin-embedded liver tissue was sliced into 5-µm sections and stained with hematoxylin and eosin (HE; Solarbio). Pathological changes in liver tissue were assessed under an optical microscope. For immunohistochemical analysis, the tissue sections were heated in citric acid buffer (0.02 mol/L, pH=5.8) (Solarbio) for antigen retrieval. Bovine serum albumin (5%; Sigma-Aldrich) in phosphate-buffered saline (PBS) was used to block non-specific binding. Then, according to the instructions of the reagent manufacturer, the sections were incubated with an anti-MyD88 antibody (Abcam, Cambridge, UK) overnight at 4°C. The sections were then incubated with a horseradish peroxidase-conjugated secondary antibody (Abcam) at 37°C for 1 h and evaluated under an optical microscope. The optical density value was calculated by ImagePro Plus software (Media Cybernetics, Inc., Rockville, MD, USA).

Enzyme-linked immunosorbent assay (referred to as ELISA)

Blood was collected from mouse eyeballs, incubated at room temperature for 30 min and centrifuged at 3,000 rpm for 15 min at 4°C. The supernatant was collected, and ELISA kits (Jiang Lai, Shanghai, China) were used to determine serum TNF-α, IL-1β, and IL-6 cytokine levels. The absorbance was measured at 450 nm in a microplate reader (ELX800; Bio-Tek, Winooski, VT, USA).

Journal of Clinical and Translational Hepatology 2021 vol. 9 | 690–701 691

Liao H. et al: Treatment of acute liver failure
Quantitative reverse transcription (qRT)-PCR

TRIzol Reagent (Solarbio) was used to extract the total RNA from mouse liver tissue, according to the manufacturer’s instructions. RNA was reverse transcribed to prepare the cDNA templates, and qRT-PCR was performed in a Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) under the following cycling conditions: initial denaturation at 95°C for 10 s, 40 cycles of a two-step PCR (95°C for 5 s, 60°C for 30 s), denaturation at 95°C for 15 s, annealing at 60°C for 1 min, and denaturation at 95°C for 15 s. β-actin was used as the housekeeping gene to normalize expression data. All expression levels were analyzed by the ΔΔCT method. Primers were designed by the Shanghai Jierui Biological Engineering Co., Ltd (Shanghai, China). The primer sequences for iκB were 5′ GGTGCAGGAGTGTGGTGGG 3′, 5′ CTGAGTGGAGTAGTGATCTGAGGC 3′; those for NF-κB were 5′ GATGTGCATCGACCTCAAG 3′, 5′ AGAAGTTGAGTTTCGGGTAG 3′; those for BcL-2 were 5′ GCTACCGTCGTGACTTCGC 3′, 5′ ATCCCAGCCACCAAGAA 3′, 5′ CAGGATGCGTCCACCAAGAA 3′; those for MyD88 were 5′ GCCCTCGCAGTTTGTTG 3′, 5′ CCACCTGACCAAGTGG 3′, 5′ AGAAGTTGAGTTTCGGGTAG 3′; those for NF-κB were 5′ GGTGCAGGAGTGTTGGTGGG 3′, 5′ CTGAGTGGAGTAGTGATCTGAGGC 3′; those for NF-κB p65 (Fig. 5), and these effects were significantly in

Western blotting

RIPA lysis buffer (Solarbio) was used to extract protein from liver tissue. A bicinchoninic acid kit (Sigma-Aldrich) was used to determine protein concentrations. Samples containing equal amounts of protein (50 μg) were subjected to electrophoresis. Proteins were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Sigma-Aldrich). The membrane was blocked with skim milk (Sigma-Aldrich) and incubated with primary antibodies (Abcam) overnight at 4°C. The next day, the membrane was incubated with Tris-buffered saline containing Tween. After washing, the membrane was incubated with the secondary antibody (Abcam) for 1.5 h at room temperature. Immunoreactions were visualized according to the instructions of the instrument manufacturers. The bands were visualized with the ChemiDoc™ XRS+; Bio-Rad, Hercules, CA, USA), and the intensities of the immunoreactive bands were measured using ImageJ analysis software (National Institutes of Health, Bethesda, MD, USA).

Data analysis

GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA, USA) statistical software was used for statistical analysis. The Kaplan-Meier method with the log rank test was used to analyze survival. Measurement data are expressed as the means±standard deviations, and analysis of variance was used to analyze survival. The Kaplan-Meier method with the log rank test was

Results

UMSC transplantation improves survival

Survival analysis is the most straightforward approach to evaluate the effect of UMSCs on ALF. As shown in Figure 1 (panels C) and Table 1, the survival rate of mice was determined every 12 h after UMSC injection. The effective trans-

plantation of UMSCs increased the survival rate by 90% at 48 h, indicating that UMSC transplantation can increase the survival rate of mice with LPS/D-GalN-induced ALF.

UMSC transplantation restores liver function

The serum ALT, AST and TBil levels in mice in the LPS/D-GalN group gradually increased with the time and duration of disease. The serum ALT level in mice in the LPS/D-GalN+UMSCs group peaked 24 h after transplantation (24±3±7±3 U/L); the AST and TBil levels peaked 12 h after transplantation (379±3±7±2 U/L; 53±9±6±1 mg/dL). Subsequently, the levels of ALT, AST, and TBil in mice in the LPS/D-GalN+UMSCs group gradually decreased with time to 63.3±2.1 U/L, 214.3±7.5 U/L, and 29.9±0.8 mg/dL, respectively, 48 h after transplantation. The ALT, AST, and TBil levels in the LPS/D-GalN+UMSCs group of mice at 12 h, 24 h, and 48 h after UMSC transplantation differed significantly from those in the LPS/D-GalN group of mice (p<0.05; Table 2). This result shows that UMSCs can significantly improve liver function.

UMSCs inhibit MyD88 expression

Liver histopathological analysis revealed the protective effect of UMSCs on LPS/GalN-induced ALF. As shown in Figure 1 (panels A–B), the normal rat liver lobular structure is typical. At 24 h after the injection of D-GalN, the control group lost its normal lobular structure, showing hepatocyte cytoplasmic edema, local regional expansion, and hepatocyte degeneration. The patchy necrosis of hepatocytes was observed, in addition to inflammatory cell infiltration in the necrotic area. At 7 days after transplantation, the LPS/D-GalN+UMSCs group showed a significant recovery in liver structure, resolution of the large areas of degenerative and necrotic liver cells, decreased inflammatory cell infiltration, and gradual recovery of the liver lobular structure. Furthermore, we observed significant bile duct hyperplasia in the portal area and normal liver cells around the bile duct. After 28 d, the liver structure basically returned to normal. Hematoxylin-eosin staining showed significant morphological changes in the transplant group compared to the control group (p<0.05).

UMSCs inhibit LPS/GalN-induced NF-κB signaling pathway activation

NF-κB is the main regulator of LPS/D-GalN-induced liver inflammation. LPS/D-GalN promoted iκB phosphorylation and degradation (Fig. 4) as well as the nuclear translocation of NF-κB p65 (Fig. 5), and these effects were significantly inhibited after UMSC transplantation. This pattern shows that the UMSC-mediated inhibition of inflammation effectively
blocked NF-κB signaling pathway activation.

**UMSCs inhibit the release of inflammatory factors**

The inflammatory cytokines TNF-α, IL-6 and IL-1β play an important role in liver injury. To further study the anti-inflammatory effect of UMSCs, their effect on serum TNF-α, IL-6 and IL-1β secretion was detected by ELISA (Fig. 6). After LPS/D-GalN treatment, the TNF-α, IL-6 and IL-1β levels in serum samples increased significantly, indicating that LPS/D-GalN can stimulate the release of these inflammatory mediators. After UMSC transplantation, the levels of these inflammatory cytokines were significantly decreased and gradually returned to normal as the survival time increased. This pattern shows that UMSCs inhibit the LPS/D-

![Figure 1](image_url)

**Fig. 1.** Liver injury gradually repaired completely after UMSC transplantation. (A–B) Representative histological changes are shown in images of liver tissue from mice in each group (hematoxylin-eosin ×100). (C) Survival curves of the LPS/D-GalN-induced ALF group, control group, and the UMSC treatment group. The survival rate of the LPS/D-GalN+UMSCs group was significantly higher than that of the LPS/D-GalN group at each time point (n=3/group, p<0.01). D-GalN, D-galactosamine; LPS, lipopolysaccharide. My D88, Myeloid differentiation factor 88.

| Time   | Number of death | Survival rate |
|--------|-----------------|---------------|
|        | LPS/D-GalN      | LPS/D-GalN+UMSCs | LPS/D-GalN      | LPS/D-GalN+UMSCs |
| 12h    | 6               | 1             | 78.6%          | 96.4%           |
| 24h    | 10              | 2             | 42.9%          | 89.3%           |
| 36h    | 7               | 0             | 17.9%          | 89.3%           |
| 48h    | 5               | 0             | 0%             | 89.3%           |

The survival rate of mice at each time point:

| Time   | Number of death | Survival rate |
|--------|-----------------|---------------|
|        | LPS/D-GalN      | LPS/D-GalN+UMSCs | LPS/D-GalN      | LPS/D-GalN+UMSCs |
| 12h    | 6               | 1             | 78.6%          | 96.4%           |
| 24h    | 10              | 2             | 42.9%          | 89.3%           |
| 36h    | 7               | 0             | 17.9%          | 89.3%           |
| 48h    | 5               | 0             | 0%             | 89.3%           |

Table 1. The survival rate of mice at each time point.

Number of deaths and survival rates at each time point in each group (n=3/group, p<0.01). D-GalN, D-galactosamine; LPS, lipopolysaccharide.
Table 2. Comparison of serum ALT, AST and TBil levels at different time points.

| Group (time point)         | AST       | ALT       | TBil     |
|---------------------------|-----------|-----------|----------|
| Control                   | 38.6±2.3  | 41.1±3.5  | 9.4±1.9  |
| LPS/D-GalN (12 h)         | 1,927±16.9* | 2,120±35.3* | 79.6±1.0* |
| LPS/D-GalN (24 h)         | 2,303.7±47.3* | 3,143±121.6* | 95.3±2.0* |
| LPS/D-GalN (48 h)         | 1,369±12.8* | 3,653±74.9* | 76±4.7*  |
| LPS/D-GalN+UMSCs (12 h)   | 233.3±13#  | 379.3±7.2# | 53.9±6.1# |
| LPS/D-GalN+UMSCs (24 h)   | 248±37.3#  | 268±23.4#  | 51.1±4.5# |
| LPS/D-GalN+UMSCs (48 h)   | 63.3±2.1#  | 214.3±7.5# | 29.9±0.8# |

Data are expressed as means±standard deviations (n=3/group): *p<0.05 vs. control; #p<0.05 vs. LPS/D-GalN. ALT, alanine aminotransferase; AST, aspartate aminotransferase; D-GalN, D-galactosamine; LPS, lipopolysaccharide; TBil, total bilirubin.

Fig. 2. Protein expression in the liver (immunohistochemistry ×100). The MyD88 expression level increased after LPS/D-GalN induction. At 7 d after transplantation, MyD88 protein expression was significantly inhibited in the LPS/D-GalN+UMSCs group. Data are presented as means±standard deviations (n=3/group). *p<0.05 vs. control; **p<0.01 vs. control; ***p<0.001 vs. LPS/D-GalN, D-GalN, D-galactosamine; LPS, lipopolysaccharide; My D88, Myeloid differentiation factor 88.
GalN-induced production of inflammatory cytokines.

**UMSCs inhibit the expression of apoptosis-related proteins**

To explore the inhibitory effect of UMSCs on LPS/D-GalN-induced hepatocyte apoptosis, we evaluated the expression of apoptosis-related signaling proteins by western blot analysis and qRT-PCR. In the LPS/D-GalN group, the expression of Bax increased, while that of Bcl-2 decreased (Fig. 7). In contrast, in the UMSC-treated group, Bax was down-regulated, and Bcl-2 was up-regulated.

**Discussion**

The liver is an important metabolic tissue and plays an im-

---

Fig. 3. mRNA (A–B) and DNA (C–E) expression of MyD88 in different groups. Data are presented as means±standard deviations (n=3/group). *p<0.05 vs. control; **p<0.01 vs. control; ***p<0.001 vs. control; *p<0.05 vs. LPS/D-GalN; **p<0.01 vs. LPS/D-GalN; ***p<0.001 vs. LPS/D-GalN. D-GalN, D-galactosamine; LPS, lipopolysaccharide; My D88, Myeloid differentiation factor 88.
Fig. 4. UMSC therapy inhibited IkB phosphorylation and degradation, mRNA (A–B) and DNA (C–D) expression of IkB in different groups, and DNA expression (E–F, G) of P-IkB in different groups. Data are presented as means±standard deviations (n=3/group). *p<0.05 vs. control; **p<0.01 vs. control; ***p<0.001 vs. control; #p<0.05 vs. LPS/D-GalN; ##p<0.01 vs. LPS/D-GalN; ###p<0.001 vs. LPS/D-GalN.D-GalN, D-galactosamine; IkB, inhibitor of nuclear factor-κB; LPS, lipopolysaccharide; P-IkB, phosphorylated-IkB; UMSCs, umbilical cord mesenchymal stem cells.

Liao H. et al: Treatment of acute liver failure
Liao H. et al: Treatment of acute liver failure

Fig. 5. UMSC therapy inhibited nuclear translocation of NF-κB p65. mRNA (A–B) of NF-κB in different groups, DNA expression (C–D, G) of Nul-NF-κB in different groups. Data are presented as mean±standard deviations (n=3/group). *p<0.05 vs. control; **p<0.01 vs. control; ***p<0.001 vs. control; #p<0.05 vs. LPS/D-GalN; ##p<0.01 vs. LPS/D-GalN; ###p<0.001 vs. LPS/D-GalN. D-GalN, cytoplasmic levels of NF-κB; D-galactosamine; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; Nul-NF-κB, nuclear levels of NF-κB; UMSCs, umbilical cord mesenchymal stem cells.
Fig. 6. Effects of UMSCs on inflammatory mediators IL-1β (A–B), IL-6 (C–D), and TNF-α (E–F) in LPS/D-GalN-induced ALF. Data are expressed as means±standard deviations (n=3/group). *p<0.05 vs. control; **p<0.01 vs. control; ***p<0.001 vs. control; ****p<0.001 vs. LPS/D-GalN. D-GalN, D-galactosamine; IL-1β, interleukin-1β; IL-6, interleukin-6; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α; UMSCs, umbilical cord mesenchymal stem cells.
important role in maintaining balance and health. ALF is a life-threatening clinical syndrome characterized by rapid development and high mortality. Finding a clinical method that can effectively treat ALF is an important challenge.
LPS/D-GaIN-induced ALF is a well-established experimental model, and inflammation is an important pathogenic mechanism of LPS/D-GaIN-induced ALF. A number of studies have shown that UMScs have the potential for self-renewal and multi-lineage differentiation into terminal cells of many tissues and organs and can participate in immunomodulation. Therefore, it was an important objective of our study to explore whether UMScs can exhibit anti-inflammatory activity and anti-apoptosis characteristics in ALF. In this study, we investigated the protective effect and the underlying mechanism of UMScs against ALF in LPS/D-GaIN-induced mice with an inflammatory response and apoptosis. The ALF model was successfully established by the intraperitoneal injection of LPS/D-GaIN. This model presented a substantial liver injury with obvious changes in histopathological and biochemical parameters. Our results showed the histopathological changes after LPS treatment, including loss of normal lobular structure and showing hepatocyte cytoplasmic edema, local regional expansion, hepatocyte degeneration, necrotic areas filled with inflammatory cells and red blood cells, and inflammatory cell infiltration. Moreover, inflammatory mediators, in turn leading to excessive Kupffer cell activity, can trigger NF-κB activation. The IKK complex is phosphorylated and catalyzes the phosphorylation of IκB, which is followed by its ubiquitination, resulting in its proteasomal degradation. Then, the IκB/NF-κB complex dissociates, resulting in the nuclear translocation of active NF-κB. Through immunohistochemical staining, qRT-PCR and western blot assay, our present study determined that the MyD88/NF-κB signaling pathway was successfully activated in the liver. LPS/D-GaIN-induced IκB phosphorylation and degradation and increased NF-κB p65 nuclear translocation, while UMScs attenuated these effects. These results indicate that UMScs partially suppress the MyD88/NF-κB signaling pathway activity by inhibiting IκB phosphorylation. Inflammatory mediators play an important role in LPS/D-GaIN-induced ALF. In the liver, LPS first binds to LPS-binding protein, is then transferred to TLR4, and is finally expressed on the surface of Kupffer cells. Activated Kupffer cells can mediate hepatitis progression by secreting TNF-α and other proinflammatory cytokines. TNF-α is an important inflammatory mediator associated with LPS/GaIN-induced liver injury and may induce hepatocyte apoptosis, which in turn leads to organ failure. In addition, TNF-α may trigger an inflammatory cascade and induce the production of other cytokines, including IL-1β and IL-6. Previous studies have reported that inhibiting TNF-α synthesis inhibits cytokine production and reduces liver damage. Our results suggest that UMScs can significantly reduce the production of the inflammatory factors TNF-α, IL-1β and IL-6 by down-regulating the expression of upstream regulators of inflammatory factors after transplantation.

Moreover, previous studies have shown that MyD88 overexpression does not immediately induce a strong apoptotic response. However, after 2–3 days, in cells with high expression of MyD88, the apoptotic response becomes apparent. Therefore, we suspect that after LPS stimulation, the MyD88-induced apoptotic pathway can become activated. Through qRT-PCR and western blot assay, our findings indicated that after LPS/D-GaIN stimulation, the expression of the antiapoptotic protein Bcl-2 was significantly down-regulated and that of the proapoptotic protein Bax was up-regulated. However, after UMSc transplantation, this effect was significantly reversed.

In summary, this study suggests that in the mouse model of LPS/D-GaIN-induced ALF, UMScs can reduce liver damage by suppressing inflammatory mediator release and apoptosis. Mechanistically, this effect is achieved via MyD88/NF-κB signaling inhibition, which finally exerts a therapeutic effect on ALF. Therefore, we believe that UMScs are a potential and valuable therapeutic alternative for ALF.

**Acknowledgments**

The corresponding author wishes to thank Zhiquan Xue for providing unlimited motivation, I will love you forever.

**Funding**

This research was supported by the National Natural Science Foundation of China (Grant No. 40117026).

**Conflict of interest**

The authors have no conflict of interests related to this publication.

**Author contributions**

Study design (HL, JY), performance of experiments (HL, SD), analysis and interpretation of data (HL, SD, TJ, MZ, ZX), manuscript writing (SD, TJ, MZ), critical revision of the manuscript (HL, SD, TJ, MZ, ZX), technical or material support (JY).

**Data sharing statement**

No additional data are available.

**References**

[1] Patel P, Okoronkwo N, Pyrsopoulos NT. Future approaches and therapeutic modalities for acute liver failure. Clin Liver Dis 2018;22(2):419–427. doi:10.1016/j.clld.2018.01.011.
[2] Dey D, Banerjee M. Inhibitor-based therapeutics for treatment of viral hepatitis. J Clin Transl Hepatol 2016;4(3):248–257. doi:10.14218/JCTH.2016.00025.
[3] Gong X, Yang Y, Huang L, Zhang Q, Wan RZ, Zhang P, et al. Antioxidation, anti-inflammation and anti-apoptosis by paenoxil in LPS/D-GaIN-induced acute liver failure in mice. Int Immunopharmacol 2017;46:124–132. doi:10.1016/j.intimp.2017.03.003.
[4] Knap JS, Mesenchymal stem cells. J Orthop Res 1991;9(5):641–650. doi:10.1002/jor.1100090504.
[5] Sun J, Zhao Y, Li Q, Chen B, Hou X, Xiao Z, et al. Controlled release of collagen-binding SDF-1α improves cardiac function after myocardial infarction by recruiting endogenous stem cells. Sci Rep 2016;6:266–283.
Liao H. et al: Treatment of acute liver failure

doi:10.1038/srep26683.

[6] Tsolalo E, Yanaki E. Stem cell-based regenerative opportunities for the liver: state of the art and beyond. World J Gastroenterol 2015;21:12334-12350. doi:10.3748/wjg.v21.i43.12334.

[7] Alfaro MP, Vincent A, Saranawati S, Thorne CA, Hong CC, Lee Es, et al. FRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 2010;285(46):35645-35653. doi:10.1074/jbc.M110.135335.

[8] Liu WH, Song FQ, Ren LN, Guo WQ, Wang T, Feng YX, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med 2015;19:511-520. doi:10.1111/jcmm.12482.

[9] Ouyang JF, Lou J, Yan C. In-vitro promoted differentiation of mesenchymal stem cells towards hepatocytes induced by salidroside. J Pharm Pharmacol 2010;62(4):530-538. doi:10.1211/jpp.62.04.0017.

[10] Ma HC, Shi XL, Ren HZ, Yuan XW, Ding YT. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration. World J Gastroenterol 2014;20(40):14884-14894. doi:10.3748/wjg.v20.i40.14884.

[11] Xu S, Teng GJ, Lu H, Jin J, Zhang Y, Zhang A, et al. In vivo differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver. Invest Radiol 2010;45(10):625-633. doi:10.1097/RLI.0b013e3181ed55f4.

[12] Zhu X, He B, Zhou X, Ren J. Effects of transplanted bone-marrow-derived mesenchymal stem cells in animal models of acute hepatitis. Cell Tissue Res 2013;351:477-486. doi:10.1007/s00441-012-1524-3.

[13] Al-Harbi NO, Imam MM, Al-Harbi MA, Ansari MA, Zoheir KM, Korashy HM, et al. Dexamethasone attenuates LPS-induced acute lung injury through inhibition of NF-kappaB, COX-2, and pro-inflammatory mediators. Immunol Invest 2016;45:349-369. doi:10.3109/08820139.2016.1157814.

[14] Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88 inhibitor TR-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice. Int Immunopharmacol 2019;67:356-365. doi:10.1016/j.intimp.2018.11.051.

[15] Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998;9(1):143-150. doi:10.1016/S1074-7613(00)80596-8.

[16] Fang X, Liu L, Dong J, Zhang J, Song H, Song Y, et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis. J Gastroenterol Hepatol 2010;33:774-780. doi:10.1111/j.1440-1746.2010.05998.x.

[17] Ma Z, Hou T, Shi W, Liu W, He H. Inhibition of hepatocyte apoptosis: an important mechanism of corn peptides attenuating liver injury induced by ethanol. Int J Mol Sci 2015;16:22062-22080. doi:10.3390/ijms160922062.

[18] Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokeine 2008;42(2):145-151. doi:10.1016/j.cyto.2008.01.006.

[19] Ding Z, Du D, Yang Y, Yang M, Mao X, Zou Z, et al. Short-term use of MyD88 inhibitor T3-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice. Int Immunopharmacol 2019;67:356-365. doi:10.1016/j.intimp.2018.11.051.

[20] Liu LM, Liang DY, Ye CG, Tu WJ, Zhu T. The U11 / UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells. PLoS One 2015;10(3):e0121383. doi:10.1371/journal.pone.0121383.

[21] Yang P, Zhou W, Li C, Zhang M, Yang Y, Jiang R, et al. Kupffer-cell-expressed transmembrane TNF-α is a major contributor to lipopolysaccharide and D-galactosamine-induced liver injury. Cell Tissue Res 2016;363(2):371-383. doi:10.1007/s00441-015-2252-2.

[22] Yamada Y, Ishizaki M, Kido T, Honda R, Tsutani I, Nogawa K, et al. Relationship between serum gamma-glutamyl transpeptidase activity, blood pressure and alcohol consumption. J Hum Hypertens 1989;3:409-417.

[23] Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-alpha therapy in uveitis. Surv Ophthalmol 2015;60:575-589. doi:10.1016/j.survophthal.2015.06.004.

[24] Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7(6):837-847. doi:10.1016/s1074-7613(00)80402-1.